Question 1

What is GLP-2 TZ?

Accepted Answer

GLP-2 TZ is a tirzepatide-class synthetic dual GIP/GLP-1 receptor agonist - the first compound class to simultaneously activate both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). CAS 2023788-19-2, MW 4813.50 g/mol. It is studied as the dual-agonist intermediate between single-agonist GLP-1 compounds (semaglutide) and triple agonists like GLP-3 RT (Retatrutide). For in vitro laboratory research use only.

Question 2

What does dual GIP/GLP-1 agonist mean?

Accepted Answer

A dual GIP/GLP-1 agonist simultaneously activates two incretin receptors: GIPR (glucose-dependent insulinotropic polypeptide receptor) and GLP-1R (glucagon-like peptide-1 receptor). GIP and GLP-1 are distinct incretin hormones with overlapping but non-identical physiological roles. GLP-2 TZ engages both simultaneously - the dual incretin approach produces pharmacological effects in research models that neither receptor alone can replicate, including additive insulin secretion, lipid metabolism effects, and energy balance modulation.

Question 3

How does GLP-2 TZ differ from semaglutide?

Accepted Answer

Semaglutide is a selective GLP-1 receptor agonist with no GIPR activity. GLP-2 TZ adds GIPR agonism alongside GLP-1R - a dual-receptor activation profile. In research models, this dual mechanism produces distinct pharmacological effects not seen with GLP-1R-only compounds, including GIPR-driven contributions to post-prandial insulin secretion, adipose lipid metabolism, and energy balance.

Question 4

How does GLP-2 TZ differ from GLP-3 RT (the triple agonist)?

Accepted Answer

GLP-2 TZ activates two receptors: GIPR and GLP-1R. GLP-3 RT (Retatrutide) adds a third - GCGR (glucagon receptor). GCGR activation is associated with hepatic glucose output and energy expenditure effects not present in GLP-2 TZ. GLP-2 TZ is the dual-agonist reference point between semaglutide (single) and GLP-3 RT (triple) - order all three to run a step-up receptor pharmacology comparison within the same class.

Question 5

What is the CAS number and molecular weight of GLP-2 TZ?

Accepted Answer

CAS number: 2023788-19-2. Molecular weight: 4813.50 g/mol. GLP-2 TZ is catalogued in the tirzepatide compound class - the first approved dual GIP/GLP-1 agonist for glucose control and weight management.

Question 6

What is GLP-2 TZ used for in research?

Accepted Answer

GLP-2 TZ is used for dual incretin receptor pharmacology studies examining combined GIPR + GLP-1R activation profiles; comparative receptor studies as the dual-agonist reference between semaglutide (single) and GLP-3 RT (triple); glucose homeostasis and post-prandial insulin secretion modeling; adipose tissue lipid metabolism research examining GIPR-driven lipogenesis and lipolysis effects; and cardiovascular outcome research examining cardiometabolic risk marker modulation by dual incretin activation.

Question 7

Is GLP-2 TZ FDA approved?

Accepted Answer

GLP-2 TZ is an investigational research compound in the tirzepatide class. Research-grade GLP-2 TZ sold here is for in vitro laboratory use only and is not approved by the FDA for therapeutic, diagnostic, or clinical application.

Question 8

What sizes are available for GLP-2 TZ?

Accepted Answer

GLP-2 TZ is available in 10mg ($89.95), 15mg ($129.95), and 30mg ($239.95) vials, all as lyophilized powder. The 15mg size is unique to GLP-2 TZ in our catalog, supporting mid-range dose protocols between pilot and full dose-response studies.

Question 9

What documentation is available with GLP-2 TZ?

Accepted Answer

A batch-specific Certificate of Analysis (COA) is publicly available for every lot, covering HPLC purity (≥99%) and LC-MS identity confirmation. Access using the lot number on your vial from the COA page.

GLP-2 TZ Tirzepatide-Class Research Peptide

Key Takeaways

Key Scientific Specifications

Research-Referenced Attributes

Also in This Research Area

Related Compounds

GLP-3 RT

GLP-3 R